DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast 2034” analysis provides comprehensive understanding of Multiple Myeloma, encompassing historical and projected epidemiology alongside market trajectories across the United States, EU4 nations (Germany, Spain, Italy, France), the United Kingdom, and Japan.
The latest healthcare forecast analysis delivers thorough examination of Multiple Myeloma, offering extensive perspectives on revenue patterns, prevalence, and treatment landscape. The analysis explores critical statistical data, emphasizing current and anticipated market valuations while evaluating effectiveness and advancement of novel therapeutic interventions. Additionally, the analysis encompasses the clinical trial ecosystem, presenting an overview of active and forthcoming research initiatives poised to influence future treatment paradigms. This document serves as a vital resource for comprehending market forces and evolving therapeutic alternatives within the Multiple Myeloma domain.
To access detailed information about the Multiple Myeloma market perspective, therapeutic adoption, treatment scenarios, and epidemiological patterns, Click here; Multiple Myeloma Market Forecast
Essential Highlights from the Multiple Myeloma Market Analysis:
The Multiple Myeloma marketplace was valued at approximately USD 21,300 million in 2023 and is projected to expand with substantial CAGR throughout the study timeframe (2020-2034).
- In March 2026, The U.S. Food and Drug Administration authorized the combination of teclistamab (Tecvayli) and daratumumab hyaluronidase-fihj (Darzalex Faspro) for managing adults with Relapsed or Refractory Multiple Myeloma (RRMM) who have previously undergone at least one line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
- In March 2026, Johnson & Johnson announced that the U.S. FDA authorized a combination therapy of TECVAYLI (teclistamab-cqyv) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for adults with RRMM who have previously received at least one line of treatment. This combination operates synergistically to stimulate and activate the immune system, enabling it to target and eliminate myeloma cells expressing the BCMA protein.
- In 2023, the total multiple myeloma marketplace in the US was approximately USD 14,300 million, with projections indicating growth by 2034.
- In the 4L+ treatment setting, authorized CAR-T therapies (ABECMA and CARVYKTI) were projected to generate approximately USD 828 million in the US in 2023, with further growth anticipated as additional CAR-T therapies receive authorization during the forecast timeline.
- In September 2025, Lupin received U.S. FDA authorization for its generic Lenalidomide Capsules, a treatment for multiple myeloma and certain cases of myelodysplastic syndromes.
- In August 2025, Regeneron Pharmaceuticals highlighted its PD-1 inhibitor Libtayo as the standard of care for advanced cutaneous squamous cell carcinoma, with ongoing research in melanoma and multiple myeloma.
- In May 2025, GSK announced that the CHMP of the EMA recommended approval of Blenrep for adults with relapsed or refractory multiple myeloma.
- In May 2025, Johnson & Johnson announced that the FDA’s Oncologic Drugs Advisory Committee voted 6-2 in favor of the benefit-risk profile of DARZALEX FASPRO® for managing high-risk smoldering multiple myeloma.
- In April 2025, Halozyme announced that the European Commission authorized an indication extension for subcutaneous DARZALEX® co-formulated with ENHANZE®.
- In February 2025, Opna Bio announced that its oral small molecule inhibitor, OPN-6602, received FDA Orphan Drug designation for multiple myeloma.
- Key Multiple Myeloma Companies: Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others
- Key Multiple Myeloma Therapies: Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI (ciltacabtagene autoleucel), TALVEY (talquetamab), ABECMA, SARCLISA
- The Multiple Myeloma marketplace is expected to expand substantially driven by growing disease prevalence and heightened awareness throughout the forecast timeline.
- In 2023, the total incidence of multiple myeloma across the 7MM was approximately 75,000 cases, with figures expected to rise over the forecast period.
- Within the 7MM, the United States documented the highest incidence of multiple myeloma, followed by the EU4 countries and the UK.
- Multiple myeloma occurs more frequently in males than females, with over 50% of cases in the United States diagnosed in men.
- Individuals aged 65 and above represent the largest proportion of multiple myeloma cases in the United States, accounting for over 70% of cases.
Understanding Multiple Myeloma
Multiple Myeloma represents a type of blood cancer affecting plasma cells, a type of white blood cell responsible for producing antibodies. In MM, abnormal plasma cells multiply uncontrollably in the bone marrow, resulting in impaired immune function, bone damage, anemia, kidney complications, and increased infection risk. The disease is typically chronic and progresses over time, with symptoms including bone pain, fatigue, frequent infections, and elevated calcium levels. Management often involves a combination of chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, and supportive care to manage symptoms and slow disease progression.
Access a Complimentary sample for the Multiple Myeloma Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/multiple-myeloma-market
Multiple Myeloma Epidemiology Analysis
The epidemiology section delivers insights into historical, contemporary, and projected epidemiological patterns across the seven major countries (7MM) spanning 2020 to 2034. It facilitates recognition of factors driving current and anticipated trends through examination of multiple studies and perspectives of key opinion leaders. The epidemiology segment additionally provides comprehensive analysis of diagnosed patient populations and emerging trends.
Epidemiology Segmentation: Multiple Myeloma
The Multiple Myeloma market analysis presents epidemiological evaluation for the 2020–2034 study period across the 7MM, categorized into:
- Total Prevalence of Multiple Myeloma
- Prevalent Cases of Multiple Myeloma by severity
- Gender-specific Prevalence of Multiple Myeloma
- Diagnosed Cases of Episodic and Chronic Multiple Myeloma
Download the comprehensive analysis to understand factors influencing Multiple Myeloma epidemiological patterns @ Multiple Myeloma Epidemiology Forecast
Multiple Myeloma Therapeutic Uptake and Pipeline Activities
The therapeutic uptake analysis concentrates on adoption rates of potential pharmaceuticals recently introduced to the Multiple Myeloma marketplace or anticipated to launch during the evaluation period. The examination encompasses market penetration by therapeutics, patient adoption by treatment modalities, and individual drug revenue.
The analysis additionally covers Multiple Myeloma Pipeline Development Activities, delivering valuable intelligence regarding various therapeutic candidates across different developmental phases and principal companies engaged in developing targeted interventions.
Multiple Myeloma Therapeutics and Principal Companies
- Zevorcabtagene Autoleucel: Carsgen Therapeutics
- Descartes 08: Cartesian Therapeutics
- GC012F: Gracell Biotechnology Shanghai Co., Ltd.
- CID-103: CASI Pharmaceuticals
- STI-1492: Sorrento Therapeutics
- CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine
- TALVEY (talquetamab): Johnson & Johnson Innovative Medicine
- ABECMA: Bristol-Myers Squibb and Bluebird bio
- SARCLISA: Sanofi
Explore additional therapies positioned to capture significant Multiple Myeloma market share @ Multiple Myeloma Treatment Landscape
Multiple Myeloma Market Growth Catalysts
- Rising global prevalence of multiple myeloma due to aging populations
- Advancements in targeted therapies, immunotherapies, and CAR-T cell treatments improving patient outcomes
- Increasing adoption of novel combination therapies and personalized medicine approaches
- Growing awareness and early diagnosis through improved diagnostic technologies
- Expansion of reimbursement and healthcare infrastructure in emerging markets
Multiple Myeloma Market Challenges
- Elevated costs of innovative therapies limiting patient access, especially in developing regions
- Complex treatment regimens resulting in patient non-compliance
- Safety and adverse effect concerns associated with long-term therapy
- Restricted availability of specialized treatment centers for advanced therapies like CAR-T
- Regulatory obstacles and lengthy approval timelines for new pharmaceuticals
Report Scope: Multiple Myeloma Market
- Study Period: 2020–2034
- Coverage: 7MM
- Key Multiple Myeloma Companies: Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others
- Key Multiple Myeloma Therapies: Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI, TALVEY, ABECMA, SARCLISA, and others
- Multiple Myeloma Therapeutic Evaluation: Current marketed and emerging therapies
- Multiple Myeloma Market Dynamics: Market growth drivers and market obstacles
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Multiple Myeloma Unmet Needs, KOL perspectives, Analyst perspectives, Market Access and Reimbursement
To discover more about Multiple Myeloma companies operating in the treatment marketplace, visit @ Multiple Myeloma Clinical Trials and Therapeutic Assessment
Table of Contents
- Multiple Myeloma Market Report Introduction
- Executive Summary for Multiple Myeloma
- SWOT analysis of Multiple Myeloma
- Multiple Myeloma Patient Share (%) Overview at a Glance
- Multiple Myeloma Market Overview at a Glance
- Multiple Myeloma Disease Background and Overview
- Multiple Myeloma Epidemiology and Patient Population
- Country-Specific Patient Population of Multiple Myeloma
- Multiple Myeloma Current Treatment and Medical Practices
- Multiple Myeloma Unmet Needs
- Multiple Myeloma Emerging Therapies
- Multiple Myeloma Market Outlook
- Country-Wise Multiple Myeloma Market Analysis (2020–2034)
- Multiple Myeloma Market Access and Reimbursement of Therapies
- Multiple Myeloma Market Drivers
- Multiple Myeloma Market Barriers
- Multiple Myeloma Appendix
- Multiple Myeloma Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About DelveInsight
DelveInsight is a prominent Healthcare Business Consultant and Market Research organization specializing exclusively in life sciences. It assists Pharmaceutical companies by delivering comprehensive end-to-end solutions to enhance their performance.
The organization additionally provides Healthcare Consulting Services, which facilitate market analysis to accelerate business expansion and address challenges with practical methodologies.
Contact Us
Kanishk
